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Evidence associating serum 25-hydroxyvitamin D (25(OH)D) concentrations and cardio-metabolic 37 
risk factors is inconsistent and studies have largely been conducted in adult populations. We examined 38 
the prospective associations between serum 25(OH)D concentrations and cardio-metabolic risk 39 
factors from adolescence to young adulthood in the West Australian Pregnancy Cohort (Raine) Study. 40 
Serum 25(OH)D concentrations, BMI, homeostatic model assessment for insulin resistance (HOMA-41 
IR), triglycerides, high-density lipoprotein-cholesterol (HDL-C) and systolic blood pressure (SBP) 42 
were measured at the 17 (n=1015) and 20 (n=1117) year follow-ups. Hierarchical linear mixed models 43 
with maximum likelihood estimation were used to investigate associations between serum 25(OH)D 44 
concentrations and cardio-metabolic risk factors, accounting for potential confounders. In males and 45 
females respectively, mean (SD) serum 25(OH)D concentrations were 73.6 (28.2) and 75.4 (25.9) 46 
nmol/L at 17 years, and 70.0 (24.2) and 74.3 (26.2) nmol/L at 20 years. Deseasonalised serum 47 
25(OH)D3 concentrations were inversely associated with BMI (Coefficient=-0.01; 95%CI -0.03,-48 
0.003; p=0.014). No change over time was detected in the association for males; for females the 49 
inverse association was stronger at 20 years compared with 17 years. Serum 25(OH)D concentrations 50 
were inversely associated with log HOMA-IR (Coefficient =-0.002; 95%CI -0.003,-0.001; p<0.001) 51 
and positively associated with log triglycerides in females (Coefficient=0.002; 95%CI 0.0008,0.004; 52 
p=0.003). These associations did not vary over time. There were no significant associations between 53 
serum 25(OH)D concentrations and HDL-C or SBP. Clinical trials in those with insufficient vitamin 54 
D status may be warranted to determine any beneficial effect of vitamin D supplementation on insulin 55 





Cardiovascular disease is the leading cause of deaths related to non-communicable diseases, and 59 
improving the detection and treatment of cardiovascular disease is a major goal of clinical medicine 60 
(1). Low serum 25-hydroxyvitamin D (25(OH)D) concentrations are frequently reported in 61 
populations worldwide (2; 3; 4; 5; 6; 7) and there are a number of potential mechanisms implicating low 62 
vitamin D status in cardio-metabolic risk. There appears to be a role for vitamin D in the development 63 
of insulin resistance: vitamin D receptors are strongly expressed in pancreatic beta-cells (8) and the 64 
active form of vitamin D (1,25-dihydroxyvitamin D) may protect against insulin resistance in 65 
peripheral tissues, such as skeletal muscle (9). Animal and in vitro studies suggest that 1,25-66 
dihydroxyvitamin D is a potent negative regulator of renin gene expression and may prevent the over-67 
stimulation of the renin-angiotensin system (10), a regulatory pathway that plays an essential role in 68 
blood pressure.  69 
 70 
A recent review of systematic reviews and meta-analyses found that highly convincing evidence of a 71 
clear role of vitamin D does not exist for cardiovascular disease, hypertension or type 2 diabetes (11). 72 
However, the epidemiological evidence associating serum 25(OH)D concentrations and cardio-73 
metabolic risk has been largely cross-sectional in design and focuses on adult populations, with 74 
conflicting results. Using data from the 17 and 20 year follow-ups of the Western Australia Pregnancy 75 
Cohort (Raine) Study, we investigated the prospective associations between serum 25(OH)D 76 
concentrations and cardio-metabolic risk factors including body mass index (BMI), insulin resistance, 77 
high-density lipoprotein cholesterol (HDL-C), triglycerides and systolic blood pressure (SBP). To 78 
our knowledge, this is the first prospective study examining associations between serum 25(OH)D 79 





The Raine Study is a prospective, population-based, longitudinal study and its methodology has been 85 
described previously (12). In brief, a total of 2900 pregnant women from the public antenatal clinic at 86 
King Edward Memorial Hospital or surrounding private clinics in Perth, Western Australia, were 87 
recruited between May 1989 and November 1991, and gave birth to 2868 live children. These children 88 
underwent assessment at birth and at ages 1, 2, 3, 5, 8, 10, 14, 17 and 20 years.  Recruitment and all 89 
follow-ups were approved by the ethics committees of King Edward Memorial Hospital for Women 90 
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and the Princess Margaret Hospital for Children, Perth, Western Australia. Informed and written 91 
consent was obtained from the participant and/or their primary caregiver at all follow-ups. 92 
 93 
Serum 25-hydroxyvitamin D concentrations 94 
Serum 25(OH)D concentrations were determined at the 17 and 20 year follow-ups. Venous blood 95 
samples were taken from an antecubital vein after an overnight fast and stored at -80°C until analysis. 96 
Serum 25(OH)D2 and 25(OH)D3 concentrations were measured using isotope-dilution liquid 97 
chromatography-tandem mass spectrometry (LC-MS/MS) (RDDT, Victoria, Australia), according to 98 
published methodology (13). The method for the quantification of vitamin D metabolites (25(OH)D2 99 
and 25(OH)D3) in serum/plasma used hexa-deuterated 25(OH)D3 as an internal standard on either the 100 
API 4000 QTRAP system or the Agilent 6410 QQQ LC-MS/MS system. Serum Calibration 101 
Standards containing nominal amounts of 25(OH)D2/25(OH)D3 from CHROMSYSTEMS were used 102 
to generate calibration curves. Tri-level Quality Control samples containing 25(OH)D2/25(OH)D3 103 
designated as Level Low, Level 1 and Level 2 were purchased from UTAK Laboratories (PM 104 
Separations). At 17 years, the coefficient of variation (CV) for 25(OH)D3 was 7.1% at 27 nmol/L, 105 
5.0% at 75 nmol/L, and 5.3% at 164 nmol/L. The CV for 25(OH)D2 was 8.8% at 23 nmol/L, 6.7% at 106 
66 nmol/L, and 6.7% at 150 nmol/L. At 20 years, the CV for 25(OH)D3 was 5.8% at 28 nmol/L, 5.2% 107 
at 80 nmol/L, and 9.2% at 188 nmol/L. The CV for 25(OH)D2 was 7.9% at 25 nmol/L, 6.6% at 75 108 
nmol/L, and 10.4% at 185 nmol/L.  109 
 110 
Cardio-metabolic risk factors 111 
Participants at 17 years were weighed to the nearest 100 g using a Wedderburn Digital Chair Scale 112 
and height was determined to the nearest 0.1 cm with a Holtain Stadiometer. At 20 years, weight was 113 
measured to the nearest 100 g using Personal Precision scales UC-321 (A and D Company) and height 114 
was measured to the nearest 0.1 cm with a wall mounted Seca 202. Body mass index (BMI) was 115 
calculated as weight in kilograms divided by height in metres squared. Fasting blood samples at the 116 
17 and 20 year follow-ups were analysed for serum glucose, HDL-C and triglycerides, determined 117 
enzymatically on an Architect c16000 Analyser (Abbott Laboratories, Lake Forest, Illinois) (intra-118 
assay CVs were 1.0% for glucose, 2.0% for HDL-C, and 1.9% for triglycerides). Serum insulin was 119 
determined on an Architect i2000SR Analyser (intra-assay CV 1.78%). The homeostatic model 120 
assessment for insulin resistance (HOMA-IR) score was calculated as follows: HOMA-IR score = 121 
(fasting insulin (µU/mL) x fasting glucose (mmol/L)) / 22.5 (14). Resting blood pressure at 17 and 20 122 
years was obtained using an oscillometric sphygmomanometer (Dinamap ProCare 100, Soma 123 
Technology, USA). After five minutes of quiet rest, six automatic recordings were taken every two 124 
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minutes with subjects supine and with an appropriate cuff size. The averages of the last five readings 125 
of SBP were calculated.  126 
 127 
Potential confounding variables 128 
Participants were classified as Caucasian if both parents were Caucasian, or as non-Caucasian if one 129 
or both parents were of an alternate ethnicity. Physical activity at the 17 year follow-up was assessed 130 
using a self-reported questionnaire based on exercise outside of school hours per week, with exercise 131 
defined in three categories as activity causing breathlessness or sweating (≥ 4 times per week, 1-3 132 
times per week and < once per week). At 20 years, physical activity was assessed using a self-reported 133 
questionnaire recording time spent in moderate or vigorous physical activity (≥ 4 times per week, 1-134 
3 times per week and < once per week).  135 
 136 
A baseline measure of family income was available at the 17 year follow-up, completed by the 137 
primary caregiver, with 12 categories ranging from $1-$8000 per year to ≥ $104,000 per year 138 
(Australian dollars). At the 17 and 20 year follow-ups, the participants answered the question “do you 139 
currently smoke cigarettes”. At the 17 and 20 year follow-ups, the use of hormonal contraception 140 
(HC) (yes/no) was reported by the participant. 141 
 142 
A self-reported, semi-quantitative food frequency questionnaire (FFQ) developed by the 143 
Commonwealth Scientific and Industrial Research Organisation in Adelaide, Australia (15) was used 144 
at the 17 year follow-up to assess alcohol intake (g/day). This 212-item FFQ assesses usual dietary 145 
intake over the previous year, collecting information on the frequency of consumption of individual 146 
foods, mixed dishes and beverages, along with information on usual serving sizes in relation to a 147 
standard serving size (in household units). Participants were asked how often they usually drank six 148 
types of alcohol (low alcohol beer, regular beer, alcoholic soda, wine/champagne, sherry/port/liqueur 149 
and spirits). Frequency was recorded as never, rarely, times per month, times per week or times per 150 
day.  151 
 152 
At the 20 year follow-up, alcohol intake (g/day) was assessed using a self-reported semi-quantitative 153 
FFQ developed by the Anti-Cancer Council of Victoria for use in the ethnically diverse Australian 154 
population (16). The questionnaire includes three questions on alcohol consumed over the last twelve 155 
months. Participants were asked to report how often they drank beer, wine and/or spirits, with six 156 
types of alcohol specified (low alcohol beer, full strength beer, red wine, white/sparkling wine, 157 
fortified wine, spirits/liqueurs) and ten frequency choices ranging from “never” to “every day”. A 158 
second question asked how many glasses of beer/wine and/or spirits they usually drank on days they 159 
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were drinking (total number of glasses per day, ranging from one to ten or more). A third question 160 
asked about the maximum number of glasses of beer/wine and/or spirits they drank in 24 hours 161 
(maximum number of glasses per 24 hours ranging from 1-2 to 19 or more).  162 
 163 
Addressing potential seasonal effects 164 
Models investigating HDL-C, trigylcerides and HOMA-IR were not adjusted for season as these 165 
biomarkers change relatively quickly over time and the blood sample for these biomarkers was taken 166 
on the same day as that for the measurement of serum 25(OH)D concentrations. Similarly, SBP 167 
changes relatively quickly over time and it would not be appropriate to adjust for season if serum 168 
25(OH)D concentrations and SBP measurements were taken on the same day. Although 95% of 169 
participants had blood for serum 25(OH)D concentrations and SBP measurements taken within 31 170 
days of each other, approximately 5% of participants had measurements taken more than 31 days 171 
apart. In order to determine if the time difference between measurement of serum 25(OH)D 172 
concentrations and SBP influenced the association between serum 25(OH)D concentrations and SBP, 173 
we deseasonalised the serum 25(OH)D3 concentrations using sine and cosine curves (17) and moved 174 
the projected date back to match the day that SBP was measured. This technique has previously been 175 
reported by Lucas and colleagues (18). For models investigating BMI, which changes relatively slowly 176 
over time, we used deseasonalised serum 25(OH)D3 concentrations (17). 177 
 178 
Statistical analyses 179 
Characteristics of the participants for whom full data for cardio-metabolic risk factors and HC were 180 
available were described at both the 17 and 20 year follow-ups. A three-level variable for sex (to 181 
distinguish females not using HC, females using HC, and males) was employed to assess the 182 
interactive effects of HC use on the relationship between serum 25(OH)D concentrations and all 183 
outcomes, except BMI. For BMI, there was no difference between females not using HC and females 184 
using HC. Additional power was required to demonstrate statistically significant differences between 185 
females and males; therefore, for the BMI model, we used a two-level variable for sex. HOMA-IR, 186 
triglycerides and HDL-C were not normally distributed, so log transformations were applied. 187 
 188 
Hierarchical linear mixed models with maximum likelihood estimation (MLE) were used to 189 
investigate associations between serum 25(OH)D concentrations and cardio-metabolic risk factors 190 
(BMI, HOMA-IR, triglycerides, HDL-C, SBP) over time. All models included adjustment for sex 191 
and BMI (excluding the model with BMI as an outcome) and investigated possible interactions 192 
between time, serum 25(OH)D concentrations and each of sex or BMI. The hierarchical structure 193 




Additional covariates (race, physical activity, family income, smoking, alcohol intake and month of 196 
birth) were then included individually to determine if a significant association with the outcome was 197 
detected or if the covariate influenced any relationship between serum 25(OH)D concentrations and 198 
the outcome. Sample sizes were held fixed for these comparisons based on the sample without 199 
missing data for each covariate in turn. Due to considerable missing data for some covariates, models 200 
utilising MLE for covariates (structural equation models in Stata) were also employed to investigate 201 
possible bias the loss of sample may have introduced. These models were not longitudinal models 202 
but rather approximations achieved by identifying repeated measures on the subject as a per person 203 
cluster, resulting in an adjusted, robust variance. The sibling adjustment was not made in these 204 
models. These models were used to determine if multiple imputation was necessary. 205 
 206 
While some of the additional covariates were significantly associated with the outcomes, the analysis 207 
determined that these associations were independent of the relationship with serum 25(OH)D 208 
concentrations. The significance of the relationship between serum 25(OH)D concentrations and the 209 
outcome was unaltered by the inclusion of the additional covariates, and variations in the magnitude 210 
of the relationships (the coefficient) were considered to be minimal (Supplementary Tables 1 and 2). 211 
Hence, it was determined that multiple imputation to facilitate inclusion of variables that had no effect 212 
on the relationship of interest was unnecessary. 213 
 214 
Analyses were performed using IBM SPSS Statistics Release Version 19.9.9.1 (IBM SPSS Inc., 2010, 215 
Chicago, IL) and StataCorp 2011 Stata Statistical Software: Release 12 (College Station, TX: 216 
StataCorp LP). Statistical significance was defined as two-tailed p < 0.05. The regression tables are 217 
reported per 1 nmol/L change in serum 25(OH)D concentrations and as log transformations of 218 




Participant characteristics 223 
Full data for outcome variables and HC were available for 1015 participants at the 17 year follow-up 224 
and 1117 participants at the 20 year follow-up. A CONSORT flow diagram is shown in Figure 1, and 225 
participant characteristics for males and females are shown in Table 1. Mean (SD) serum 25(OH)D 226 
concentrations were 73.6 (28.2) and 75.4 (25.9) nmol/L at the 17 year follow-up in males and females, 227 
respectively; and 70.0 (24.2) and 74.3 (26.2) nmol/L at the 20 year follow-up in males and females, 228 
respectively. At the 17 year follow-up, only 4 participants had detectable serum 25(OH)D2 229 
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concentrations, ranging from 5.44 to 8.12 nmol/L. At the 20 year follow-up, 13 participants had 230 
detectable serum 25(OH)D2 concentrations, ranging from 5.24 to 7.07 nmol/L. 231 
 232 
Deseasonalised serum 25-hydroxyvitamin D3 concentrations and BMI 233 
In a univariate analysis, deseasonalised serum 25(OH)D3 concentrations were inversely associated 234 
with BMI (Coefficient=-0.02; 95%CI -0.03,-0.02; p<0.001) and the association persisted after 235 
adjusting for sex (Table 2). A significant three way interaction between time, sex and serum 236 
25(OH)D3 concentrations indicated that the relationship between serum 25(OH)D3 concentrations 237 
and BMI changed over time differently in males compared to females (p=0.026).  No change over 238 
time was detected in the association for males, whereas for females the inverse association was 239 
stronger at 20 years compared with 17 years (Figure 2). The model estimates that a one standard 240 
deviation increase in serum 25(OH)D3 concentrations (approximately 25 nmol/L) was associated with 241 
a reduction in BMI of 0.4 kg/m2 in females at 17 years; 0.6 kg/m2 in females at 20 years; 0.6 kg/m2 242 
in males at 17 years; and 0.5 kg/m2 in males at 20 years. 243 
 244 
Serum 25-hydroxyvitamin D concentrations and insulin resistance 245 
In a univariate model, serum 25(OH)D concentrations were inversely associated with log HOMA-IR 246 
(Coefficient=-0.003; 95%CI -0.005, -0.002; p<0.001) and the inverse association was maintained 247 
after adjusting for BMI (Coefficient=-0.002; 95%CI -0.003, -0.001; p<0.001) (Table 3). No 248 
significant interactions were found between time, serum 25(OH)D concentrations and each of sex or 249 
BMI. The model estimates that a one standard deviation increase in serum 25(OH)D concentrations 250 
was associated with a 5% decrease in HOMA-IR. 251 
 252 
Serum 25-hydroxyvitamin D concentrations and triglycerides 253 
In a univariate model, serum 25(OH)D concentrations were positively associated with log 254 
triglycerides (Coefficient=0.001; 95%CI 0.0004, 0.002; p=0.03). A significant interaction between 255 
serum 25(OH)D concentrations and sex indicated the relationship between serum 25(OH)D 256 
concentrations and log triglycerides differed in males when compared to females (p=0.016).  There 257 
was a positive association in females not using HC after adjusting for BMI (Coefficient=0.0023; 258 
95%CI 0.0008, 0.0038; p=0.003) (Table 4), and a similar effect in females using HC. Coefficients 259 
from the model estimate that a one standard deviation increase in serum 25(OH)D concentrations was 260 
associated with a 6% increase in triglycerides in females. There was no significant association 261 
between serum 25(OH)D concentrations and triglycerides in males (p=0.738). 262 
 263 
Serum 25-hydroxyvitamin D concentrations and HDL-C 264 
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Serum 25(OH)D concentrations were positively associated with log HDL-C in a univariate model 265 
(Coefficient=0.0005; 95%CI 0.0002, 0.0008; p=0.004). However, there was no association between 266 
serum 25(OH)D concentrations and HDL-C after adjusting for BMI (Supplementary Table 3) and no 267 
significant interactions were found between time, serum 25(OH)D concentrations and each of sex or 268 
BMI. 269 
 270 
Serum 25-hydroxyvitamin D concentrations and SBP 271 
There was no difference in the relationship between serum 25(OH)D concentrations and SBP when 272 
we moved the projected date of blood measurement back to match the day that SBP was measured. 273 
Therefore, we did not deseasonalise serum 25(OH)D concentrations or adjust for season in models 274 
with SBP as the outcome measure. An inverse association between serum 25(OH)D concentrations 275 
and SBP (Coefficient=-0.02; 95%CI -0.04, -0.003; p=0.023) in a univariate analysis was not 276 
significant after adjusting for BMI (Supplementary Table 4). No significant interactions were found 277 




This study has shown that serum 25(OH)D concentrations were inversely associated with BMI and 282 
HOMA-IR in an adolescent and young adult population. Serum 25(OH)D concentrations were 283 
positively associated with triglycerides in females only. There were no significant associations 284 
between serum 25(OH)D concentrations and HDL-C or SBP. 285 
 286 
The inverse association between deseasonalised serum 25(OH)D3 concentrations and BMI was 287 
consistent between 17 and 20 years in males, but increased over time in females. Similarly, an inverse 288 
association between serum 25(OH)D concentrations and waist circumference was identified by 289 
Gagnon and colleagues in a prospective study of 4164 adults participating in The Australian Diabetes, 290 
Obesity and Lifestyle (AusDiab) Study (19), and by Ganji and colleagues in a cross-sectional study of 291 
5867 adolescents participating in the United States’ National Health and Nutrition Examination 292 
Survey (NHANES) (20).  293 
 294 
We found a significant inverse association between serum 25(OH)D concentrations and HOMA-IR, 295 
a result which is supported by a number of other studies in children and adolescents (20; 21; 22; 23; 24; 25; 296 
26), including the study by Ganji and colleagues (20). The prospective study by Gagnon and colleagues 297 
also found that serum 25(OH)D concentrations were inversely associated with HOMA-IR in adults 298 
(19). However, Nam and colleagues found no significant associations between serum 25(OH)D 299 
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concentrations and insulin resistance or fasting glucose in a cross-sectional study of 1504 children 300 
and adolescents participating in the Korean NHANES, after adjusting for age, sex, physical activity, 301 
alcohol consumption and supplement use (27). Although a six-month trial supplementing 4000 IU/day 302 
of vitamin D in 35 obese adolescents found significant improvements in HOMA-IR compared with 303 
placebo (28), vitamin D supplementation trials in adults have shown mixed results on glycaemic status, 304 
insulin resistance and insulin sensitivity (29; 30; 31; 32; 33; 34; 35; 36; 37; 38; 39; 40; 41). 305 
 306 
There may be associations between vitamin D responsiveness, vitamin D-receptor (VDR) gene 307 
polymorphisms and insulin resistance. Associations between single nucleotide polymorphisms 308 
(SNPs) and responses in insulin sensitivity to vitamin D supplementation of 4000 IU per day were 309 
determined in 81 South Asian women (42). The improvement in insulin sensitivity was significantly 310 
greater in women with the FokI Ff genotype compared with women with the FokI FF genotype. 311 
Therefore, differences in the VDR gene may explain differences in response of insulin sensitivity to 312 
vitamin D supplementation. Further explorations of the influence of SNPs on responsiveness of 313 
cardio-metabolic risk factors to vitamin D intervention are warranted. 314 
 315 
We found a positive association between serum 25(OH)D concentrations and triglycerides in females. 316 
Other observational studies have shown an inverse association (19; 43), or no association (27), between 317 
circulating 25(OH)D concentrations and triglycerides. However, our finding was supported by a 318 
recent randomised controlled trial in 200 hypertensive adults with low serum 25(OH)D 319 
concentrations: Pilz and colleagues showed that vitamin D supplementation significantly increased 320 
triglycerides compared with placebo (44). Although the authors hypothesised that this result was a 321 
chance finding, they noted that further validation from additional studies was warranted. In contrast, 322 
a trial in 200 healthy overweight subjects participating in a 12 month weight-reduction programme 323 
found that, compared with the placebo group, vitamin D supplementation lowered triglycerides but 324 
increased LDL-C (45). We found no statistically significant associations between serum 25(OH)D 325 
concentrations and HDL-C, which is supported by the studies by Nam and colleagues, and Gagnon 326 
and colleagues (19; 27). A recent review of vitamin D supplementation and lipid profile found that most 327 
randomised controlled trials showed no effects, or even adverse effects, on serum lipids (46). 328 
 329 
We found no independent association between serum 25(OH)D concentrations and SBP. This finding 330 
conflicts with a systematic review and meta-analysis of 22 cross-sectional studies and eight 331 
prospective studies (largely in adult populations), which showed that circulating 25(OH)D 332 
concentrations were inversely associated with risk of hypertension (47). However, the results of 333 
vitamin D supplement trials and SBP are equivocal. A meta-analysis of 16 randomised trials of 334 
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vitamin D supplementation on blood pressure in adults showed an overall non-significant reduction 335 
in both SBP and diastolic blood pressure (48). The trial by Pilz and colleagues showed that vitamin D 336 
supplementation had no significant effect on SBP (44). 337 
 338 
There is growing interest in the health effects of sun exposure beyond the synthesis of vitamin D, and 339 
it is plausible that serum 25(OH)D concentrations are merely a biomarker of previous sun exposure. 340 
Recent in vivo experiments indicate that chronic skin exposure to low dose ultraviolet radiation 341 
(UVR) limits the development of obesity and signs of metabolic syndrome in mice fed a high fat diet 342 
(49). Skin exposure to UVR induces several immune effector molecules, and low-dose UVR irradiation 343 
of the skin has been shown to lower blood pressure in healthy volunteers independently of vitamin 344 
D, through modulation of nitric oxide bioavailability (50). Further investigations to elucidate the 345 
vitamin D-independent effects of low-dose exposure to UVR on cardio-metabolic risk factors are 346 
warranted. 347 
 348 
Strengths of our study include the young age of the cohort, and the prospective design based on a 349 
longitudinal cohort. We were able to investigate confounders that potentially impact upon serum 350 
25(OH)D concentrations and cardio-metabolic risk factors, including race, month of birth, BMI, 351 
physical activity, family income, hormonal contraceptive use, smoking and alcohol intake. However, 352 
despite our best efforts to adjust for confounders, we cannot rule out the possibility of residual 353 
confounding. Weaknesses of our study include the measurement of physical activity, which was not 354 
based on a validated questionnaire and may be subject to self-reporting bias. Furthermore, our 355 
assessment of physical activity did not differentiate between indoor and outdoor activity. The non-356 
significance of physical activity in relation to cardio-metabolic risk factors may reflect the limitations 357 
of the measurement, rather than the true absence of an association between physical activity and the 358 
outcome. In light of the evidence associating genetic factors with responses in insulin resistance to 359 
vitamin D supplementation (42), it is possible that genetic variation may modify the association 360 
between serum 25(OH)D concentrations and cardio-metabolic risk factors. In our study, no data were 361 
available for genetic factors relating to vitamin D; further studies in this area would benefit from 362 
investigating factors such as the FokI Ff genotype.  363 
 364 
Although we used the same laboratory for measurement of serum 25(OH)D concentrations using LC-365 
MS/MS methods at both follow-ups, this laboratory was not participating in an external quality 366 
control scheme at the time of analysis. Laboratories using LC-MS/MS methods have been shown to 367 
give higher results than those certified to the international standard reference method developed by 368 
the National Institute of Standards and Technology and Ghent University (51), which may have partly 369 
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contributed to the relatively high serum 25(OH)D concentrations in our population. Given that our 370 
population of adolescents/young adults has relatively high vitamin D status in comparison with those 371 
in other countries (52), our findings may not be generalisable to all populations. Furthermore, although 372 
the availability of data from two cohort follow-ups in adolescence and young adulthood enabled us 373 
to examine changes over time, we cannot infer causality in the relationship between serum 25(OH)D 374 
concentrations and cardio-metabolic risk factors.  375 
 376 
Our results show that serum 25(OH)D concentrations are independently associated with a number of 377 
cardio-metabolic risk factors in adolescents and young adults, with differential effects on BMI with 378 
time between sexes. In particular, the finding that serum 25(OH)D concentrations were inversely 379 
associated with BMI and insulin resistance would suggest a cardio-protective benefit, but this may be 380 
offset by the positive association between serum 25(OH)D concentrations and triglycerides. Well-381 
designed clinical trials in those with insufficient vitamin D status may be warranted to determine any 382 
causal, beneficial effect of vitamin D supplementation on insulin resistance in adolescents and young 383 
adults, while monitoring for any deleterious effect on triglycerides. 384 
 385 
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Table 1. Characteristics of the Raine Study participants for whom full data for outcome variables and hormonal contraceptive use were available 396 
 397 
25(OH)D, 25-hydroxyvitamin D; HOMA-IR, homeostatic model assessment for insulin resistance; LDL-C, low-density lipoprotein; HDL-C, high-398 
density lipoprotein; SBP, systolic blood pressure; BMI, body mass index; NA, not applicable; NR, not reported.399 
n n n n
Race (% Caucasian) 453 85 407 85 505 84 447 86
Serum 25(OH)D [nmol/L, mean (SD)] 534 73.6 (28.2) 481 75.4 (25.9) 598 70.0 (24.2) 519 74.3 (26.2)
HOMA-IR [median (IQR)] 534 1.5 (1.3) 481 1.6 (1.3) 598 0.5 (0.7) 519 0.6 (0.9)
Total cholesterol [mmol/L, mean (SD)] 534 3.9 (0.7) 481 4.3 (0.7) 598 4.2 (0.8) 519 4.5 (0.8)
LDL-C [mmol/L, mean (SD)] 534 2.2 (0.7) 481 2.4 (0.6) 598 2.4 (0.7) 519 2.6 (0.6)
HDL-C [mmol/L, median (IQR)] 534 1.2 (0.3) 481 1.4 (0.4) 598 1.2 (0.3) 519 1.4 (0.4)
Triglycerides [mmol/L, median (IQR)] 534 0.9 (0.5) 481 0.9 (0.5) 598 1.0 (0.6) 519 1.0 (0.6)
SBP [mm/Hg, mean (SD)] 534 120.2 (10.2) 481 110.1 (9.6) 598 123.4 (12.6) 519 111.4 (11.2)
BMI [kg/m2, mean (SD)] 534 22.8 (4.3) 481 23.2 (4.6) 598 24.5 (2.5) 519 24.3 (5.4)
Physical activity (%)
     ≥ 4 times per week 143 33 77 18 329 73 218 47
     1-3 times per week 273 54 231 53 75 17 141 30
     < once per week 59 13 125 29 47 10 107 23
Family income at 17 years (%)
     ≤ $40,000 per year 119 25 125 28 NR NR NR NR
     $40,001-78,000 per year 176 37 172 38 NR NR NR NR
     > $78,000 per year 185 39 151 34 NR NR NR NR
Hormonal contraceptive use (% Current user) NA NA 155 32 NA NA 308 59
Smoking (% Current smoker) 96 19 111 23 73 16 62 13
Alcohol consumers (%) 201 59 201 56 511 92 469 94
Alcohol intake in consumers [g/day, median (IQR)] 6.0 (12.3) 5.4 (8.9) 15.9 (30.0) 8.4 (16.4)
Male Female Male Female
17 year follow-up (n =1015) 20 year follow-up  (n =1117)
 
 
Table 2. Adjusted associations between deseasonalised serum 25(OH)D3 concentrations and 400 
body mass index 401 
 402 
25(OH)D3, 25-hydroxyvitamin D3 403 
1Estimated difference in body mass index from the reference category of categorical variables 404 
or per 1 unit increase of continuous variables  405 
2Coefficient for females, 17 year follow-up 406 
Females, 20 year follow-up: Coefficient= -0.03; 95%CI -0.04, -0.02; p<0.001 407 
Males, 17 year follow-up: Coefficient= -0.03; 95%CI -0.04, -0.01; p<0.001  408 
Males, 20 year follow-up: Coefficient= -0.02; 95%CI -0.03, -0.01; p=0.001   409 
Variable Coefficient (95% CI)1 p
Deseasonalised 25(OH)D3 (nmol/L) -0.01 (-0.03, -0.003)
2 0.014
Time
     20 year follow-up 1.96 (1.08, 2.85) <0.001
Sex
     Male 0.33 (-0.94, 1.61) 0.610
Time*25(OH)D3
     20 year follow-up -0.01 (-0.02, -0.0002) 0.047
Time*Sex
     20 year, Male -0.82 (-2.02, 0.39) 0.182
Sex*25(OH)D3
     Male -0.01 (-0.03, 0.005) 0.190
Time*Sex*25(OH)D3
     20 year, Male 0.02 (0.002, 0.03) 0.026
Constant 24.47 (23.52, 25.42) <0.001
 
 
Table 3. Adjusted associations between serum 25(OH)D concentrations and log homeostatic 410 
model assessment for insulin resistance 411 
 412 
HC, hormonal contraception; 25(OH)D, 25-hydroxyvitamin D 413 
1Estimated difference in log homeostatic model assessment for insulin resistance from the 414 
reference category of categorical variables or per 1 unit increase of continuous variables 415 
  416 
Variable Coefficient (95% CI)1 p
25(OH)D (nmol/L) -0.002 (-0.003, -0.001) <0.001
Time
     17 year follow-up Reference
     20 year follow-up -0.86 (-0.91, -0.81) <0.001
Sex
     Female Reference
     Female using HC 0.18 (0.10, 0.26) <0.001
     Male 0.01 (-0.06, 0.08) 0.814
Body mass index (kg/m2) 0.06 (0.06, 0.07) <0.001
Constant -0.93 (-1.11, -0.74) <0.001
 
 
Table 4. Adjusted associations between serum 25(OH)D concentrations and log triglycerides 417 
 418 
HC, hormonal contraception; 25(OH)D, 25-hydroxyvitamin D 419 
1Estimated difference in log triglycerides from the reference category of categorical variables 420 
or per 1 unit increase of continuous variables 421 
2Coefficient for females not using HC 422 
Males: Coefficient=0.00015; 95%CI -0.0008, 0.001; p=0.738 423 
  424 
Variable Coefficient (95% CI)1 p
25(OH)D (nmol/L) 0.0023 (0.0008, 0.0038)2 0.003
Time
     20 year follow-up -0.12 (-0.17, -0.06) <0.001
Sex
     Female using HC 0.24 (0.08, 0.40) 0.003
     Male 0.25 0.12, 0.39) <0.001
Time*Sex
     20 year, Female using HC 0.08 (-0.01, 0.17) 0.070
     20 year, Male 0.11 (0.04, 0.18) 0.001
Sex*25(OH)D
     Female using HC -0.0003 (-0.0021, 0.0016) 0.779
     Male -0.0021 (-0.0038, -0.0004) 0.016
Body mass index (kg/m2) 0.03 (0.02, 0.03) <0.001
Constant -0.95 (-1.11, -0.80) <0.001
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Figure 2. A graphical representation of the three-way interaction in the BMI model showing an 583 
inverse association between deseasonalised serum 25-hydoxyvitamin D3 concentrations and BMI 584 
that does not change over time in males, but is stronger in females at 20 years compared with 17 585 
years. 586 
25(OH)D, 25-hydoxyvitamin D 587 
Supplementary Table 1. Effect of covariates, missingness and modelling technique on estimated serum 25(OH)D coefficient for models with SBP, log 
HDL-C and log Homa-IR as outcomes 































   Serum 25(OH)D coefficient and p values 
SBP   0.00225 0.806         
 Alcohol 0.006   0.00848 0.41 0.00448 0.67 0.00565 0.60 0.00305 0.74 
 Family income 0.23   -0.00189 0.87 -0.00346 0.77 -0.00227 0.85 0.00459 0.62 
 Smoking 0.998   -0.00151 0.87 -0.00151 0.87 0.00149 0.88 0.00676 0.47 
 Physical activity 0.82   0.00159 0.87 0.00277 0.78 0.00510 0.62 0.00828 0.39 
 Race2 0.38     0.00082 0.93 0.00451 0.64   
log HDL-C   0.00010 0.528         
 Alcohol <0.001   0.00006 0.76 -0.00004 0.81 0.00006 0.76 0.00009 0.65 
 Family income 0.56   -0.00004 0.87 -0.00005 0.81 0.00001 0.98 0.00020 0.30 
 Smoking 0.34   0.00011 0.53 0.00011 0.52 0.00020 0.32 0.00022 0.23 
 Physical activity 0.18   0.00009 0.60 0.00003 0.85 0.00006 0.79 0.00013 0.51 
 Race2 0.034     0.00016 0.34 0.00031 0.10   
log Homa-IR   -0.00216 <0.001         
 Alcohol 0.84   -0.00223 <0.001 -0.00222 <0.001 -0.00231 <0.001 -0.00223 <0.001 
 Family income 0.64   -0.00226 0.002 -0.00219 0.002 -0.00237 0.003 -0.00222 <0.001 
 Smoking 0.85   -0.00209 <0.001 -0.00208 <0.001 -0.00220 <0.001 -0.00226 <0.001 
 Physical activity 0.12   -0.00230 <0.001 -0.00208 0.001 -0.00214 0.001 -0.00201 0.001 
 Race2 0.68     -0.00221 <0.001 -0.00235 <0.001   
 
(A): Hierarchical LMM adjusting for sex and BMI, reported as final model 
(B): Hierarchical LMM based on sample with covariate data (reduced due to missing data on covariate), without covariate included in the model 
(C): Hierarchical LMM (B) with covariate included in the model 
(D): Clustered analysis of model with covariate included without MLE 
(E): Same as (D) with MLE for missing covariate data 
The difference between Models C and D illustrates the difference between Hierarchical LMM and clustered analysis, which tends to result in a loss of 
power. 
The difference between Models D and F illustrates the potential impact of missing data. 
1In Hierarchical LMM in reduced sample 
2No missing data 
No data supplied for BMI outcome as no covariates were significantly associated with outcome. 
25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; HC, hormonal contraception; HDL-C, high-density lipoprotein cholesterol; HOMA, 







Supplementary Table 2. Effect of covariates, missingness and modelling technique on estimated serum 25(OH)D coefficient for models with log 
triglycerides as outcome 































  Serum 25(OH)D coefficient and p values 
25(OH)D  0.00228 0.003         
Sex*25(OH)D            
     Females using HC  -0.00026 0.78         
     Males  -0.00212 0.016         
Alcohol 0.002           
25(OH)D    0.00212 0.012 0.00204 0.015 0.00155 0.067 0.00170 0.023 
Sex*25(OH)D            
     Females using HC    -0.00006 0.96 -0.00008 0.94 -0.00022 0.84 -0.00069 0.49 
     Males    -0.00211 0.033 -0.00225 0.022 -0.00176 0.093 -0.00151 0.11 
Family income 0.851           
25(OH)D    0.00276 0.005 0.00275 0.005 0.00203 0.02 0.00175 0.02 
Sex*25(OH)D            
     Females using HC    -0.00023 0.84 -0.00021 0.85 -0.00061 0.58 -0.00064 0.52 
     Males    -0.00238 0.035 -0.00237 0.035 -0.00127 0.29 -0.00135 0.15 
Smoking 0.003           
25(OH)D    0.00224 0.003 0.00217 0.004 0.00180 0.02 0.00171 0.022 
Sex*25(OH)D            
     Females using HC    -0.00023 0.81 -0.00009 0.92 -0.00054 0.6 -0.00050 0.62 
     Males    -0.00227 0.011 -0.00227 0.011 -0.00166 0.085 -0.00142 0.13 
Physical activity 0.122           
25(OH)D    0.00230 0.004 0.00247 0.002 0.00217 0.01 0.00201 0.008 
Sex*25(OH)D            
     Females using HC    -0.00022 0.83 -0.00027 0.79 -0.00069 0.52 -0.00078 0.43 
     Males    -0.00241 0.011 -0.00243 0.01 -0.00187 0.07 -0.00144 0.12 
Race2 0.276           
25(OH)D      0.00237 0.002 0.00186 0.014   
Sex*25(OH)D            
     Females using HC      -0.00030 0.75 -0.00070 0.48   
     Males      -0.00215 0.015 -0.00140 0.14   
 
(A): Hierarchical LMM adjusting for sex and BMI, reported as final model 
(B): Hierarchical LMM based on sample with covariate data (reduced due to missing data on covariate), without covariate included in the model 
(C): Hierarchical LMM (B) with covariate included in the model 
(D): Clustered analysis of model with covariate included without MLE 
(E): Same as (D) with MLE for missing covariate data 
The difference between Models C and D illustrates the difference between Hierarchical LMM and clustered analysis, which tends to result in a loss of 
power. 
The difference between Models D and F illustrates the potential impact of missing data. 
1In Hierarchical LMM in reduced sample 
2No missing data 
25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; HC, hormonal contraception; HDL-C, high-density lipoprotein cholesterol; HOMA, 
homeostatic model assessment for insulin resistance; LMM, linear mixed model; MLE, maximum likelihood estimation; SBP, systolic blood pressure 
 
Supplementary Table 3. Associations between serum 25-hydroxyvitamin D and log HDL-C 
  
1Estimated difference in log high-density lipoprotein from the reference category of categorical 
variables or per 1 unit increase of continuous variables  
25(OH)D, 25-hydroxyvitamin D; HC, hormonal contraception 
  
Variable Coefficient (95% CI)
1
p
25(OH)D (nmol/L) 0.0001 (-0.0002, 0.0004) 0.528
Time
     17 year follow-up Reference
     20 year follow-up 0.04 (0.03, 0.06) <0.001
Sex
     Female not using HC Reference
     Female using HC -0.01 (-0.03, 0.01) 0.441
     Male -0.15 (-0.17, -0.13) <0.001
Body mass index (kg/m
2
) -0.01 (-0.02, -0.01) <0.001
Constant 0.65 (0.59, 0.71) <0.001
 
Supplementary Table 4. Associations between serum 25-hydroxyvitamin D and SBP 
 
1Estimated difference in systolic blood pressure from the reference category of categorical variables 
or per 1 unit increase of continuous variables  
25(OH)D, 25-hydroxyvitamin D; HC, hormonal contraception 
 
 
Variable Coefficient (95% CI)
1
p
25(OH)D (nmol/L) 0.002 (-0.02, 0.02) 0.820
Time
     17 year follow-up Reference
     20 year follow-up 1.10 (0.34, 1.86) 0.005
Sex
     Female not using HC Reference
     Female using HC 2.02 (0.71, 3.33) 0.003
     Male 12.20 (11.04, -13.35) <0.001
Body mass index (kg/m
2
) 0.74 (0.64, 0.841) <0.001
Constant 91.47 (88.42, 94.52) <0.001
